1. Home
  2. CE vs BLTE Comparison

CE vs BLTE Comparison

Compare CE & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Celanese Corporation

CE

Celanese Corporation

HOLD

Current Price

$45.50

Market Cap

5.4B

Sector

Industrials

ML Signal

HOLD

Logo Belite Bio Inc

BLTE

Belite Bio Inc

HOLD

Current Price

$171.35

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CE
BLTE
Founded
1918
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
6.0B
IPO Year
2004
2021

Fundamental Metrics

Financial Performance
Metric
CE
BLTE
Price
$45.50
$171.35
Analyst Decision
Buy
Strong Buy
Analyst Count
14
7
Target Price
$64.29
$198.00
AVG Volume (30 Days)
1.4M
175.7K
Earning Date
05-05-2026
05-08-2026
Dividend Yield
0.18%
N/A
EPS Growth
23.62
N/A
EPS
1.54
N/A
Revenue
$9,544,000,000.00
N/A
Revenue This Year
$3.14
N/A
Revenue Next Year
$2.83
$492.11
P/E Ratio
$30.40
N/A
Revenue Growth
N/A
N/A
52 Week Low
$35.13
$68.21
52 Week High
$70.70
$200.00

Technical Indicators

Market Signals
Indicator
CE
BLTE
Relative Strength Index (RSI) 48.56 52.75
Support Level $43.78 $167.80
Resistance Level $45.64 $172.02
Average True Range (ATR) 1.66 8.15
MACD 0.15 -0.63
Stochastic Oscillator 35.09 43.03

Price Performance

Historical Comparison
CE
BLTE

About CE Celanese Corporation

Celanese is one of the world's largest producers of acetic acid and its downstream derivative chemicals, which are used in various end markets, including coatings and adhesives. The company is also one of the largest producers of specialty polymers, which are used in the automotive, electronics, medical, building, and consumer end markets. The company also makes cellulose derivatives used in cigarette filters.

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

Share on Social Networks: